A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics
Ratings for Stoke Therapeutics (NASDAQ:STOK) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Stoke Therapeutics, revealing an average target of $24.2, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 3.2% decline, the current average is now lower than the previous average price target of $25.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
A clear picture of Stoke Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joseph Stringer | Needham | Maintains | Buy | $22.00 | $22.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $35.00 | $35.00 |
| Sumant Kulkarni | Canaccord Genuity | Lowers | Buy | $20.00 | $21.00 |
| Joseph Stringer | Needham | Maintains | Buy | $22.00 | $22.00 |
| Joseph Stringer | Needham | Maintains | Buy | $22.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Stoke Therapeutics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Stoke Therapeutics compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Stoke Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Stoke Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Stoke Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering Stoke Therapeutics: A Closer Look
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
Financial Insights: Stoke Therapeutics
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Stoke Therapeutics's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -18.17%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Stoke Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -625.57% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Stoke Therapeutics's ROE excels beyond industry benchmarks, reaching -17.59%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Stoke Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -12.17%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.02, Stoke Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.